Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 * ECOG Performance Status 0-1 * HCC with histological diagnosis or non-invasive diagnosis according to AASLD criteria * Non operable and not accessible to ablation therapy * At least one measurable lesion using mRECIST * Tumor involvement \<50% of the liver * BCLC classification A to C * Compensated cirrhosis (Child Pugh A or B7), if cirrhosis present * Registration with a social security scheme * Written and informed consent of the patient or his/her legal representative Exclusion Criteria: * Inadequate hematological, hepatic, renal, thyroid and coagulation functions: 1. Hemoglobin \< 8,5 g/dl 2. Granulocytes \< 1500/mm3 3. Platelets\< 50 000 /mm3 4. Bilirubin level ≥ 35 mol/l 5. Transaminases \> 6 UNL 6. Creatinine \> 1,5 UNL 7. TSH \< 0,2 µUI/L * Chronic respiratory insufficiency history * Known hemophilia with exophytic tumor \> 1 cm * Extra-hepatic metastasis except hilum node \< 2 cm * Lung shunt \>20% evaluated with 99mTc albumin macroaggregate (MAA) * Poor tumor targeting with 99mTc albumin macroaggregate (MAA) * Previous SIRT * Previous systemic treatment within 4 weeks before radioembolization * More than 2 previous TACE (or embolization), in the area to be treated * Other neoplasia except if complete remission from at least one year * Contraindication related to the technique, in particular severe arterial pathology of the lower limbs or the aorta contraindicating or making difficult an arteriography by femoral approach * Pregnant woman or likely to be or breastfeeding, or male or female patients of reproductive potential without effective contraception from screening to 1 month after the end of the treatment * Minors, individual deprived of liberty, or under any kind of guardianship or trusteeship. * Patients unable to submit to medical follow-up of the study for social, medical or psychological reasons.